It was shown that co-administration of TGF-β–blocking and anti–PD-L1 antibodies reduced TGF-β signaling in stromal cells, facilitated T-cell penetration into the center of tumors, and provoked vigorous anti-tumor immunity and tumor regression [143]. Here, TGFB1 is linked to neoplasm.